|

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

RECRUITINGSponsored by Neurogen Biomarking LLC
Actively Recruiting
SponsorNeurogen Biomarking LLC
Started2025-01-13
Est. completion2026-03-20
Eligibility
Age40 Years – 90 Years
Healthy vol.Accepted
Locations5 sites
View on ClinicalTrials.gov →

NCT07701161

Summary

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Eligibility

Age: 40 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed

Exclusion Criteria:

* Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

Conditions4

Alzheimer's DiseaseBiomarkersMCI Conversion to DementiapTau217

Locations5 sites

Illinois

1 site
Insigth Hospital and Medical Center Chicago
Chicago, Illinois, 60616
Ansam Eghzawi, MD+18109410076ansam@neurogenbiomarking.com

Michigan

3 sites
Insight Hospital and Medical Center Dearborn
Dearborn, Michigan, 48126
Insight Institute of Neurology and Neurosurgery
Flint, Michigan, 48507
Memorial Healthcare Hospital
Owosso, Michigan, 48867

North Carolina

1 site
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157

Find trials near these locations

Alzheimer's Disease trials in ChicagoAll trials in IllinoisAll trials in North Carolina

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.